Contemporary data from a large cohort in Ontario [10, 11] suggest that GFR among women with schizophrenia increased between 1996 and 2009, which the study authors hypothesize may be due to prescription trends in Ontario towards ‘prolactin-sparing’ atypicals, such as Olanzapine, Quetiapine and Ziprasidone, rather than Prolactin-raising typical antipsychotics, or Prolactin-neutral Clozapine. This evidence concerns the gene PRL and schizophrenia.